Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

NCT03520712 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Early rollover into long-term extension study

Conditions

Hemophilia A
Gene Therapy
Clotting Disorders
Blood Disorder

Interventions

BIOLOGICAL: Valoctocogene Roxaparvovec

Sponsor

BioMarin Pharmaceutical